Trials / Completed
CompletedNCT00079989
Study Evaluating Tigecycline in Selected Serious Infections Due to Resistant Gram-Negative Organisms
A Phase 3, Open-label, Noncomparative Study of Tigecycline for the Treatment of Subjects With Selected Serious Infections Due to Resistant Gram-negative Organisms Such as Enterobacter Species, Acinetobacter Baumannii, and Klebsiella Pneumoniae
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 115 (actual)
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the safety and efficacy of tigecycline in the treatment of subjects with selected serious infections caused by resistant gram-negative bacteria, eg, Acinetobacter baumannii, Enterobacter species, Klebsiella pneumoniae or other resistant gram-negative pathogens, for whom antibiotics have failed or who cannot tolerate other appropriate antimicrobial therapies. The primary efficacy endpoint will be the clinical response.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | tigecycline |
Timeline
- Start date
- 2003-12-01
- Primary completion
- 2005-11-01
- Completion
- 2005-11-01
- First posted
- 2004-03-23
- Last updated
- 2013-02-08
Source: ClinicalTrials.gov record NCT00079989. Inclusion in this directory is not an endorsement.